Significance of Markers of Monocyte Activation (CD163 and sCD14) and Inflammation (IL-6) in Patients Admitted for Alcohol Use Disorder Treatment.
Adult
Alcoholism
/ blood
Antigens, CD
/ blood
Antigens, Differentiation, Myelomonocytic
/ blood
Biomarkers
/ blood
Cohort Studies
Female
Humans
Interleukin-6
/ blood
Lipopolysaccharide Receptors
/ blood
Male
Middle Aged
Monocytes
/ metabolism
Patient Admission
Receptors, Cell Surface
/ blood
Spain
/ epidemiology
Substance Abuse Treatment Centers
/ methods
Alcohol Use Disorder
Monocyte Activation
Systemic Inflammation
Journal
Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
10
04
2019
accepted:
30
10
2019
pubmed:
5
12
2019
medline:
7
2
2021
entrez:
5
12
2019
Statut:
ppublish
Résumé
Monocyte activation and inflammation are prominent features of alcohol-related liver disease; however, they have not been thoroughly assessed in patients with alcohol use disorder (AUD) without overt liver disease. This study aimed to analyze associations among clinical and laboratory variables and markers of monocyte activation (CD163 and sCD14), and inflammation (interleukin [IL]-6) among AUD patients. We analyzed the aforementioned associations in the highest quartile in 289 patients (77.5% male; median age, 50 years) consecutively admitted for alcohol detoxification in 2 tertiary hospitals in the Barcelona metropolitan area, Spain. Median alcohol intake was 142 g/d; median glucose, albumin, creatinine, and bilirubin levels (mg/dl), 92, 40, 0.78, and 0.69, respectively; median AST, 41 U/l; median hemoglobin, median corpuscular volume, and platelet count, 14.1 g/dl, 94.8 fL, and 189 × 10 Monocyte activation and systemic inflammation are associated with higher glucose, liver enzyme, and lipid levels, HCV infections, and CRP of >5 mg/l, thus potentially identifying patients with AUD at high risk of midterm poor outcomes.
Sections du résumé
BACKGROUND
Monocyte activation and inflammation are prominent features of alcohol-related liver disease; however, they have not been thoroughly assessed in patients with alcohol use disorder (AUD) without overt liver disease. This study aimed to analyze associations among clinical and laboratory variables and markers of monocyte activation (CD163 and sCD14), and inflammation (interleukin [IL]-6) among AUD patients.
METHODS
We analyzed the aforementioned associations in the highest quartile in 289 patients (77.5% male; median age, 50 years) consecutively admitted for alcohol detoxification in 2 tertiary hospitals in the Barcelona metropolitan area, Spain.
RESULTS
Median alcohol intake was 142 g/d; median glucose, albumin, creatinine, and bilirubin levels (mg/dl), 92, 40, 0.78, and 0.69, respectively; median AST, 41 U/l; median hemoglobin, median corpuscular volume, and platelet count, 14.1 g/dl, 94.8 fL, and 189 × 10
CONCLUSIONS
Monocyte activation and systemic inflammation are associated with higher glucose, liver enzyme, and lipid levels, HCV infections, and CRP of >5 mg/l, thus potentially identifying patients with AUD at high risk of midterm poor outcomes.
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
Biomarkers
0
CD163 antigen
0
IL6 protein, human
0
Interleukin-6
0
Lipopolysaccharide Receptors
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
152-158Subventions
Organisme : Ministry of Economy and Competitiveness, Institute of Health Carlos III
ID : RD16/0017/0003
Pays : International
Organisme : Ministry of Economy and Competitiveness, Institute of Health Carlos III
ID : PI17/00174
Pays : International
Organisme : Rio Hortega Program
ID : CM17/022
Pays : International
Organisme : European Fund for Regional Development (FEDER)
Pays : International
Organisme : Ministry of Health, Social Services and Equality, National Plan on Drugs
ID : 2015/027
Pays : International
Organisme : Ministry of Health, Social Services and Equality, National Plan on Drugs
ID : 2018/020
Pays : International
Organisme : Gilead Fellowship Program
ID : GLD17/00187
Pays : International
Organisme : Health Department Intensification Program
ID : SLT006/17/00107
Pays : International
Organisme : Consolidated Research Group
ID : 2017-SGR-316
Pays : International
Organisme : Autonomous Government of Catalonia, Spain
Pays : International
Informations de copyright
Copyright © 2019 by the Research Society on Alcoholism.
Références
Ajmera VH, Terrault NA, Harrison SA (2017) Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology 65:2090-2099.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM IV-TR). Government Printing Office, Washington, DC.
Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE (2015) Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 163:215-223.
Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112-117.
Capeau J (2011) Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis 53:1127-1129.
Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377:2063-2072.
Donnadieu-Rigole H, Mura T, Portales P, Duroux-Richard I, Bouthier M, Eliaou J-F, Perney P, Apparailly F (2016) Effects of alcohol withdrawal on monocyte subset defects in chronic alcohol users. J Leukoc Biol 100:1191-1199.
Donnadieu-Rigole H, Pansu N, Mura T, Pelletier S, Alarcon R, Gamon L, Perney P, Apparailly F, Lavigne J-P, Dunyach-Remy C (2018) Beneficial effect of alcohol withdrawal on gut permeability and microbial translocation in patients with alcohol use disorder. Alcohol Clin Exp Res 42:32-40.
Fuster D, Garcia-Calvo X, Zuluaga P, Rivas I, Sanvisens A, Tor J, Muga R (2018) Ultrasound findings of liver damage in a series of patients consecutively admitted for treatment of alcohol use disorder. Drug Alcohol Depend 190:195-199.
Fuster D, Samet JH (2018) Alcohol use in patients with chronic liver disease. N Engl J Med 379:2577-2579.
Fuster D, Sanvisens A, Bolao F, Serra I, Rivas I, Tor J, Muga R (2015a) Impact of hepatitis C virus infection on the risk of death of alcohol-dependent patients. J Viral Hepat 22:18-24.
Fuster D, Sanvisens A, Bolao F, Zuluaga P, Rivas I, Tor J, Muga R (2015b) Markers of inflammation and mortality in a cohort of patients with alcohol dependence. Medicine (Baltimore) 94:e607.
Fuster D, Tor J, Rey-Joly C, Muga R (2012) Pathogenic interactions between alcohol and hepatitis C. Med Clin (Barc) 138:627-632.
Gao B, Ahmad MF, Nagy LE, Tsukamoto H (2019) Inflammatory pathways in alcoholic steatohepatitis. J Hepatol 70:249-259.
GBD 2016 Alcohol Collaborators (2016) Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 392:1015-1035.
Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA, Lederman MM (2014) Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 210:1228-1238.
Kirpich IA, McClain CJ, Vatsalya V, Schwandt M, Phillips M, Falkner KC, Zhang L, Harwell C, George DT, Umhau JC (2017) Liver injury and endotoxemia in male and female alcohol-dependent individuals admitted to an alcohol treatment program. Alcohol Clin Exp Res 41:747-757.
Lackner C, Tiniakos D (2019) Fibrosis and alcohol-related liver disease. J Hepatol 70:294-304.
Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Stärkel P, Windey K, Tremaroli V, Bäckhed F, Verbeke K, de Timary P, Delzenne NM (2014) Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA 111:E4485-E4493.
Liangpunsakul S, Toh E, Ross RA, Heathers LE, Chandler K, Oshodi A, McGee B, Modlik E, Linton T, Mangiacarne D, Jimenez C, Dong XC, Wang L, Tu W, Nelson DE (2017) Quantity of alcohol drinking positively correlates with serum levels of endotoxin and markers of monocyte activation. Sci Rep 7:4462.
Lien E, Aukrust P, Sundan A, Müller F, Frøland SS, Espevik T (1998) Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 92:2084-2092.
Louvet A, Mathurin P (2015) Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 12:231-242.
Mandrekar P, Bala S, Catalano D, Kodys K, Szabo G (2009) The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol (Baltimore, Md 1950) 183:1320-1327.
Muga R, Sanvisens A, Jarrin I, Fuster D, Bolao F, Tor J, Muñoz A (2018) Hepatitis C infection substantially reduces survival of alcohol-dependent patients. Clin Epidemiol 10:897-905.
Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, Kang YJ, Keshavarzian A, Rao R, Sartor RB, Swanson C, Turner JR (2008) Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 42:349-361.
Rehm J, Samokhvalov AV, Shield KD (2013) Global burden of alcoholic liver diseases. J Hepatol 59:160-168.
Rivas I, Sanvisens A, Bolao F, Fuster D, Tor J, Pujol R, Torrens M, Rey-Joly C, Muga R (2013) Impact of medical comorbidity and risk of death in 680 patients with alcohol use disorders. Alcohol Clin Exp Res 37:E221-E227.
Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC (2011) Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141:1220-1230.e3.
Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H (2018) Alcoholic liver disease. Nat Rev Dis Prim 4:16.
Sobell LC, Sobell M (1992) Timeline Follow-back: a technique for assessing self-reported ethanol consumption, in Measuring Alcohol Consumption: Psychosocial and Biological Methods. (Allen J, Litten R eds), pp. 41-72, Humana Press, Totowa, NJ.
Szabo G (1999) Consequences of alcohol consumption on host defence. Alcohol Alcohol 34:830-841.
Szabo G (2015) Gut-liver axis in alcoholic liver disease. Gastroenterology 148:30-36.
Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN (2016) Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend 169:101-109.
Urbaschek R, McCuskey RS, Rudi V, Becker KP, Stickel F, Urbaschek B, Seitz HK (2001) Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 25:261-268.
World Medical Association General Assembly (2001) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects revised October 7, 2000. HIV Clin Trials 2:92-95.